The Global Atopic Dermatitis Drugs Market is estimated to reach at high CAGR during the forecast period (2022-2029).
Atopic dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages and result from a complex interplay of environmental, immunological, genetic, and pharmacologic factors. It's common in children but can occur at any age. Atopic dermatitis is long-lasting (chronic) and tends to flare periodically.
The global atopic dermatitis drug market growth is driven by the increasing prevalence of the allergic reactions, including food allergy, rising campaigns for awareness and high R&D in this field, these factors will drive the global atopic dermatitis drugs market growth in the forecast period.
Growing prevalence of food allergies that are exacerbating atopic dermatitis fuel the market growth
The increasing growth in the global atopic dermatitis drugs market is due to the growing prevalence of food allergies exacerbating atopic dermatitis. Allergy of any kind plays a vital role in the life of a person with atopic dermatitis. This condition generally flares when a person with atopic dermatitis disease is around substances that can cause allergic reactions. Primarily affecting children and infants, atopic dermatitis is estimated to account for around 10 to 20% of those suffering from eczema, according to the data of the American College of Allergy, Asthma & Immunology.
According to research, food allergy and severe atopic dermatitis coexist in approximately one-third of all children with atopic dermatitis. These food allergies are mainly caused by chicken eggs, cow’s milk, peanuts, wheat, nuts, soy, and fish. Also, atopic dermatitis once appeared in childhood can exacerbate with time.
Additionally, skin irritants occur due to certain soaps, detergents, perfumes, etc. Thus, allergic reactions, mainly due to food, are among the significant factors increasing the burden of atopic dermatitis and driving the market growth.
Rise in awareness regarding the availability of treatments for the disease is driving the market growth
A rise in awareness regarding the availability of treatments for the disease has helped the market gain traction over the past few years. In addition, initiatives undertaken by governments to provide better and more affordable treatment and the presence of favorable reimbursement policies are likely to provide an upthrust to the market. Furthermore, growing acceptance of targeted therapies such as Eucrisa and Dupixent is also working in favor of the market.
For instance, approximately 60.0% of patients with AD develop symptoms in the first year, and roughly 90.0% of patients show symptoms by the age of five (atopic march). Disease onset after 30 is rare and may be caused by exposure to harsh environmental conditions.
On the other hand, affordable healthcare plans are being executed in all leading countries, influencing company price plans and adjustment possibilities. Nevertheless, there are various opportunities where a permanent cure for the disorder could be produced by the key players or develop a systematic treatment to recover affected patients from atopic eczema infections.
High cost of therapeutics is likely to hinder the market growth
However, the high cost of therapeutics is one of the critical roadblocks in the market's upward climb. Heightened cost consciousness, especially in emerging countries, is anticipated to hinder premium-pricing opportunities for upcoming AD drugs, particularly biologics. However, reasonable healthcare measures are being incorporated across all major regions, impacting companies' pricing strategies and reimbursement scenarios.
COVID-19 Impact Analysis
COVID-19, primarily a respiratory disease, causes severe illness, is not known. Exaggerated innate inflammatory and impaired adaptive immune responses have been observed. Atopic dermatitis is associated with multimorbidity and typified by innate and adaptive immune dysregulation, which is targeted by immunomodulatory therapies. In the context of COVID‐19, the broad immune suppression conferred by conventional systemic agents, such as methotrexate, may reduce protective host antiviral immune responses. On the other hand, should treatment need to be paused in the pandemic, the longer half‐life and individual pharmacokinetics of biological therapies will limit the speed of their systemic clearance. Although real‐world observationaldata suggest an increased risk of severe infections with some agents,5, 6, their relative safety concerning COVID‐19 is unknown—conversely, immunomodulators' theoretical protective role in attenuating a severe systemic inflammatory response to infection. Thus, the pandemic has hindered the growth of the atopic dermatitis drugs market in the forecast period.
Corticosteroids segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Corticosteroids are referred to as cortisone-like medicines used as pain relief medication for inflammation in the body. These drugs are known to have reduced itching, swelling, allergic reactions, and redness. Additionally, these drugs are used as first-line treatment for different diseases, such as skin problems, severe allergies, arthritis, and asthma. Around 30 corticosteroid compounds have been licensed for atopic dermatitis treatment, of which hydrocortisone is considered the first. The rising innovations have led to the advent of counterfeit medicines and alternative drugs, such as immuno-modulators pimecrolimus and tacrolimus. However, these alternatives have pitfalls, such as selective effectivity and high cost. Hence, topical corticosteroids play a vital role in atopic dermatitis treatment.
Topical PDE4 inhibitor drugs have positive market growth in the forecast period. Healthcare companies in the atopic dermatitis drugs market are developing new drug agents to expand the treatment options for the disease. They are developing new moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs. Manufacturers are making these treatment options available at retail and hospital pharmacies. After several clinical trials, healthcare companies are introducing efficacious ointments that provide a result-oriented outcome in patients.
The topical route of administration (ROA) segment are expected to dominate the atopic dermatitis drugs market, by route of administration, during the forecast period
Topical ROA is the most effective treatment with minor side effects. These drugs are applied directly to the skin, like ointments or creams. Topical corticosteroids are the most widely prescribed medications for AD. They are often administered in combination with moisturizers or emollients for more effective results. The high incidence and prevalence of skin disease and increase in the incidence rate of bone disorders are driving the topical drugs market. The rise in painless treatments, such as topical patches, for chronic diseases is further driving the segment growth. For instance, in 2017, Dupixent’s launched injectables in the AD therapeutic landscape. However, topicals are estimated to maintain their lead through 2022.
The oral segment has favorable market growth in the forecast period. The antibiotics given for oral treatment are also used for intravenous treatments. These antibiotics effectively manage atopic dermatitis, especially when the skin shows signs of bacterial infection such as weeping, bumps, crusting, or painful swelling (cellulitis).
North America region holds the largest market share in the global atopic dermatitis drugs market
North America is expected to provide high business growth for the atopic dermatitis market over the forecast period. The factors, such as high treatment awareness among the patient population across the United States and Canada, healthcare infrastructure, early adoption of novel medications, better reimbursement policies, and increasing business partnerships of pharmaceutical companies with contract research organizations in the emerging markets, help the lucrative nature of this market in North America. Increasing incidence of atopic dermatitis, soaring treatment rate, and inflated drug prices are key trends augmenting revenue generation in the region. All such factors combine to add to the growth of the North American atopic dermatitis drugs market during the forecast period.
The atopic dermatitis drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Bayer, Sanofi, Pfizer Inc., Novartis International AG, Allergan PLC, Abbvie Inc., Meda Pharmaceuticals, JW Pharmaceutical, Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd., Wuhan Disel Biotechnology Co., Ltd., and Qingdao Hiseeking Enterprises Co., Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the atopic dermatitis drugs market globally.
Overview: JW Pharmaceutical Corp. (formerly Choongwae Pharma) pharmaceutical firms in Korea with core competencies in IV solutions, antibiotics and anti-cancer treatments. JW is currently investigating targeted therapies in oncology, leveraging the collaborative research and development intensities from the JW Drug Discovery Center in Korea and the JW Theriac Corp in the US. JW Group consists of JW Pharmaceutical, JW Holdings, JW Medical, JW Industrial, JW ShinYak, JW Life Science, and JW Creagene.
Product Portfolio: The Company’s portfolio comprises endocrinology, gastroenterology, oncology, cardiology, nephrology, urology and the general surgery therapeutic areas.
Key Development: In August 2018, JW Pharmaceutical and LEO Pharma A/S signed a licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma, a global leader in medical dermatology, gained exclusive rights to develop and commercialize JW1601, globally, excluding South Korea.
Get your free sample proposal with a single click!